Anxiety Disorders in General Medical Practice
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Timely diagnosis and early initiation of adequate therapy of disorders of the alarming spectrum (AS) remains one of the urgent tasks of modern medicine. The article considers aspects of diagnosis and treatment of AS in General medical network, particularly were described the currently recommended schemes of application of the drug Eglonil and benefits of this drug.
Eglonil demonstrates the possibility of wide application of different variants of anxiety disorders, which gives the drug a special status among other psychotropic compounds.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Васюк Ю.А., Довженко Т.В., Школьник Е.Л., Ющук Е.В. Депрессия и хроническая сердечная недостаточность при сердечно-сосудистых заболеваниях. – М., 2008.
Медведев В.Э. Диагностика и лечение тревожных расстройств // Вопросы врачебной практики. – 2011. – № 2. – С. 52-55.
Медведев В.Э., Копылов Ф.Ю., Троснова А.П. и др. Психосоматическое соотношения при кризовом течении гипертонической болезни // Психические расстройства в общей медицине. – 2007. – № 1. – С. 10-3.
Смулевич А.Б., Дробижев М.Ю., Иванов С.В. Транквилизаторы производные бензодиазепина в психиатрии, психосоматике и общей медицине. – М., 2005.
Смулевич А.Б., Медведев В.Э. Психические расстройства у больных с инфарктом миокарда. В кн. Острый коронарный синдром. А.Л. Сыркин, Н.А. Новикова, С.А. Терехин. – М.: МИА, 2010. – С. 123-36.
American Neuropsychiatric Association Annual Meeting Abstracts. The Journal of Neuropsychiatry and Clinical Neurosciences April 2015, Vol. 27, № 2. – Р. 179-203.
Bell C, Bhikha S, Colhoun H, Carter F, Frampton C, Porter R. The response to sulpiride in social anxiety disorder: D2 receptor function. J Psychopharmacol. 2013 Feb;27(2):146-51. doi: 10.1177/0269881112450778. Epub 2012 Jun 28.
Bollmann AF, Seitz W, Prasse C, Lucke T, Schulz W, Ternes T. Occurrence and fate of amisulpride, sulpiride, and lamotrigine in municipal wastewater treatment plants with biological treatment and ozonation. J Hazard Mater. 2016 Dec 15;320:204-215.
Kato K. Response of patients in mixed state of anxiety and depression to low dose sulpiride. Igaku Kenkyu. 1993 Feb;63(1):15-9.
Medvedev V, Tereshchenko O, Kost N, Ter-Israelyan A, Gushanskaya E, Chobanu IK, Sokolov O, Myasoedov N. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40.
Nutt D., Feeney A., Argyropolous S. Anxiety disorders comorbid with depression: panic disorder and agoraphobia // Martin Dunitz. 2012. – 111 p.
Nutt D., Ballenger J. Anxiety disorders. Generalized anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder // Blackwell Publishing. 2005. – 242 p.
Pélissolo A, Maniere F, Boutges B, Allouche M, Richard-Berthe C, Corruble E. Anxiety and depressive disorders in 4,425 long term benzodiazepine users in general practice. Encephale. 2007 Jan-Feb;33(1):32-8.
Vil’yanov V, Kremenitskaya S, Solov’eva N. The efficacy of sulpiride in patients with anxiety disorders depending on the serum serotonin concentrations. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(10):62-5.
